Investing.com - Pasithea Therapeutics reported on Wednesday third quarter earnings that missed analysts' forecasts and revenue that topped expectations.
Pasithea Therapeutics announced earnings per share of $-0.17 on revenue of $218.6K. Analysts polled by Investing.com anticipated EPS of $-0.14 on revenue of $100K.
Pasithea Therapeutics shares are down 42% from the beginning of the year and are trading at $1.01 , down-from-52-week-high.
Pasithea Therapeutics follows other major Healthcare sector earnings this month
Pasithea Therapeutics's report follows an earnings beat by Eli Lilly on Tuesday, November 1, 2022, who reported EPS of $1.98 on revenue of $6.94B, compared to forecasts EPS of $1.91 on revenue of $6.91B.
AbbVie had beat expectations on Friday, October 28, 2022 with third quarter EPS of $3.66 on revenue of $14.81B, compared to forecast for EPS of $3.58 on revenue of $14.93B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar